SSB
TEVA icon

Sandy Spring Bank’s Teva Pharmaceuticals TEVA Stock Holding History

Sandy Spring Bank’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$7.68K Hold
500
– – ﹤0.01% 884
2024
Q4 		$11K Hold
500
– – ﹤0.01% 842
2024
Q3 		$9.01K Hold
500
– – ﹤0.01% 871
2024
Q2 		$8.13K Hold
500
– – ﹤0.01% 903
2024
Q1 		$7.05K Sell
500
-100
-17% -$1.26K ﹤0.01% 909
2023
Q4 		$6.26K Buy
600
+100
+20% +$934 ﹤0.01% 891
2023
Q3 		$5.1K Hold
500
– – ﹤0.01% 921
2023
Q2 		$3.77K Hold
500
– – ﹤0.01% 1004
2023
Q1 		$4.42K Hold
500
– – ﹤0.01% 942
2022
Q4 		$4.56K Hold
500
– – ﹤0.01% 938
2022
Q3 		$4K Buy
+500
New +$4.42K ﹤0.01% 966
2020
Q3 		– Sell
-300
Closed -$3K – 985
2020
Q2 		$3K Buy
300
+200
+200% +$2.26K ﹤0.01% 810
2020
Q1 		$1K Hold
100
– – ﹤0.01% 880
2019
Q4 		$1K Hold
100
– – ﹤0.01% 823
2019
Q3 		$1K Hold
100
– – ﹤0.01% 830
2019
Q2 		$1K Hold
100
– – ﹤0.01% 821
2019
Q1 		$2K Hold
100
– – ﹤0.01% 761
2018
Q4 		$2K Sell
100
-428
-81% -$8.77K ﹤0.01% 751
2018
Q3 		$11K Sell
528
-200
-27% -$4.64K ﹤0.01% 669
2018
Q2 		$17K Sell
728
-405
-36% -$8.26K ﹤0.01% 605
2018
Q1 		$20K Buy
1,133
+100
+10% +$1.95K ﹤0.01% 605
2017
Q4 		$20K Sell
1,033
-390
-27% -$5.87K ﹤0.01% 594
2017
Q3 		$25K Sell
1,423
-30,606
-96% -$689K ﹤0.01% 542
2017
Q2 		$1.08M Sell
32,029
-5,587
-15% -$173K 0.11% 181
2017
Q1 		$1.22M Sell
37,616
-913
-2% -$31.2K 0.12% 174
2016
Q4 		$1.42M Sell
38,529
-27,868
-42% -$1.11M 0.15% 165
2016
Q3 		$3.08M Buy
66,397
+631
+1% +$32.9K 0.33% 77
2016
Q2 		$3.36M Sell
65,766
-7,674
-10% -$409K 0.38% 68
2016
Q1 		$3.93M Sell
73,440
-1,204
-2% -$70.6K 0.45% 62
2015
Q4 		$4.9M Sell
74,644
-3,396
-4% -$210K 0.57% 45
2015
Q3 		$4.41M Buy
78,040
+1,888
+2% +$122K 0.54% 50
2015
Q2 		$4.5M Buy
76,152
+859
+1% +$53K 0.51% 56
2015
Q1 		$4.69M Buy
75,293
+575
+0.8% +$33.4K 0.54% 53
2014
Q4 		$4.3M Sell
74,718
-1,252
-2% -$69.8K 0.52% 63
2014
Q3 		$4.08M Sell
75,970
-1,650
-2% -$87.4K 0.5% 63
2014
Q2 		$4.07M Sell
77,620
-2,435
-3% -$124K 0.51% 62
2014
Q1 		$4.23M Sell
80,055
-4,043
-5% -$187K 0.65% 50
2013
Q4 		$3.37M Sell
84,098
-30,692
-27% -$1.21M 0.48% 69
2013
Q3 		$4.34M Sell
114,790
-728
-0.6% -$28.4K 0.64% 45
2013
Q2 		$4.53M Buy
+115,518
New +$4.5M 0.71% 39

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Sandy Spring Bank's TEVA Position: Q1 2025 in Review

Sandy Spring Bank held its Teva Pharmaceuticals (TEVA) position steady in Q1 2025 at 500 shares worth $7.68K. The position accounts for ﹤0.01% of the portfolio, ranked #884.

Sandy Spring Bank first reported a position in TEVA in Q2 2013 and has held it in 40 quarters since. The position peaked at $4.9M in Q4 2015. 561 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • Sandy Spring Bank held 500 shares of Teva Pharmaceuticals worth $7.68K as of Q1 2025.
  • Sandy Spring Bank left its Teva Pharmaceuticals share count unchanged in Q1 2025.
  • Teva Pharmaceuticals made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #884 holding.
  • Sandy Spring Bank first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
  • Sandy Spring Bank's Teva Pharmaceuticals position peaked at $4.9M in Q4 2015.
  • 561 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.